Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8902346 | 0.79 | CHRNA7 (0.46) | CHRNA7OPRM1OPRK1KMT2AKDM4E | |
| SCHEMBL10060259 | 0.78 | XIAP (0.39) | CHRNA7OPRM1OPRK1KDM4EALDH1A1 | |
| SCHEMBL13818380 | 0.75 | OPRK1 (0.47) | CHRNA7OPRM1OPRK1KMT2AKDM4E | |
| SCHEMBL8900986 | 0.75 | OPRK1 (0.47) | CHRNA7OPRM1OPRK1KMT2AKDM4E | |
| SCHEMBL8901154 | 0.71 | OPRM1 (0.46) | CHRNA7OPRM1OPRK1ALDH1A1POLB | |
| SCHEMBL29161630 | 0.70 | MGLL (0.48) | CHRNA7OPRM1OPRK1KMT2AKDM4E | |
| SCHEMBL4500495 | 0.69 | MGLL (0.60) | CHRNA7OPRM1OPRK1KDM4EALDH1A1 | |
| SCHEMBL7373733 | 0.69 | MGLL (0.53) | CHRNA7OPRM1OPRK1KDM4EALDH1A1 | |
| Iodide SCHEMBL7009470 | 0.68 | OPRM1 (0.53) | CHRNA7OPRM1OPRK1 | |
| SCHEMBL10346054 | 0.68 | DRD4 (0.46) | KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550453-B2 | Anticancer agents; colon cancer or hepatocellular carcinoma; analogs of bengamide where the caprolactam ring is changed and/or substituted e.g. N-(2-Methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide | AVENTIS PHARMA SA (FR) | 2009-06-23 | — | — | US | disclosed |
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | HCCS, ALKBH2, ALKBH3 | CHRNA7 4790/4885OPRM1 2488/4885OPRK1 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.